PredicineCARE, a urine-based test, is under FDA review as a companion diagnostic for bladder cancer, building on previous data and biomarker insights. PredicineCARE, a urine next-generation sequencing ...
Roche has found redemption in a precision medicine approach following an earlier Tecentriq trial flop in a broader bladder cancer population. Tecentriq helped certain patients with muscle-invasive ...
TipRanks on MSN
Pacific Edge Faces Challenges with Cxbladder Test Volumes Amid Medicare Coverage Loss
Pacific Edge Limited ( ($PFGTF) ) has provided an update. Pacific Edge Limited reported a decline in Cxbladder test volumes due to the loss of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback